Eiger BioPharmaceuticals, Inc. Contracts & Agreements

Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and Its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code (Filed With SEC on September 9, 2024)

Lonafarnib Antiviral Asset Purchase Agreement, dated August 1, 2024, by and between Eiger InnoTherapeutics, Inc. and Eiger BioPharmaceuticals, Inc (Filed With SEC on August 2, 2024)

Peginterferon Lambda Asset Purchase Agreement, dated August 1, 2024, by and between Eiger InnoTherapeutics, Inc. and Eiger BioPharmaceuticals, Inc (Filed With SEC on August 2, 2024)

Asset Purchase Agreement, dated June 21, 2024 (Filed With SEC on June 21, 2024)

Asset Purchase Agreement, dated June 13, 2024 (Filed With SEC on June 14, 2024)

Asset Purchase Agreement, dated March 31, 2024, by and between Sentynl Therapeutics, Inc. and Eiger BioPharmaceuticals, Inc (Filed With SEC on April 1, 2024)

Offer Letter Agreement/Employment Agreement, dated as of November 25, 2019, by and between Eiger BioPharmaceuticals, Inc. and Ingrid Choong (Filed With SEC on November 9, 2023)

Promotion Letter Agreement, dated as of September 21, 2023, by and between Eiger BioPharmaceuticals, Inc. and Ingrid Choong (Filed With SEC on November 9, 2023)

Offer Letter Agreement, dated as of (Filed With SEC on August 14, 2023)

Consulting Agreement, dated as of March 10, 2023, by and between Eiger BioPharmaceuticals, Inc. and Danforth Advisors, LLC (Filed With SEC on August 14, 2023)

Amended and Restated Employment Terms, by and between Eiger BioPharmaceuticals, Inc. and David Apelian, dated as of June 28, 2023 (Filed With SEC on June 30, 2023)

Separation Agreement and General Release, dated as of February 6, 2023, by and between Eiger BioPharmaceuticals, Inc. and David A. Cory (Filed With SEC on March 17, 2023)

Offer Letter Agreement, dated as of January 9, 2023, by and between Eiger BioPharmaceuticals, Inc. and David Apelian (Filed With SEC on March 17, 2023)

Second Amendment to Lease, dated February 16, 2023, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC (Filed With SEC on March 17, 2023)

Loan and Security Agreement (Filed With SEC on June 7, 2022)

Common Stock Purchase Agreement (Filed With SEC on June 7, 2022)

Open Market Sale AgreementSM, dated March 25, 2022, by and between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on March 25, 2022)

Amendment No. 4 to Loan and Security Agreement, dated March 10, 2020, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 10, 2022)

Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Erik Atkisson, dated as of August 26, 2021 (Filed With SEC on November 4, 2021)

Amendment No. 6 to Loan and Security Agreement, dated October 6, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on November 4, 2021)

2021 Inducement Plan (Filed With SEC on August 5, 2021)

Form of Restricted Stock Unit Award Grant Notice and Award Agreement under 2013 Equity Incentive Plan (Filed With SEC on May 6, 2021)

Asset Purchase Agreement, dated September 25, 2015, by and between Eiger BioPharmaceuticals, Inc. and Tracey McLaughlin and Colleen Craig (Filed With SEC on March 9, 2021)

License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Corporation (Filed With SEC on March 9, 2021)

License Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company (Filed With SEC on March 9, 2021)

Amendment No. 6 to License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 9, 2021)

Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and The Progeria Research Foundation (Filed With SEC on March 9, 2021)

Asset Purchase Agreement, by and between Eiger BioPharmaceuticals, Inc. and AbbVie Inc., dated as of November 20, 2020 (Filed With SEC on March 9, 2021)

Amendment No. 7 to License Agreement, dated November 3, 2020, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 9, 2021)

Amendment No. 5 to Loan and Security Agreement, dated February 23, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 9, 2021)

Open Market Sale AgreementSM, dated August 6, 2020, between Eiger BioPharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 6, 2020)

Amendment No. 1, dated June 15, 2020, to the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and the Progeria Research... (Filed With SEC on August 6, 2020)

Offer Letter Agreement, by and between the Registrant and Eldon Mayer, dated as of December 3, 2019 (Filed With SEC on May 7, 2020)

Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 7, 2020)

Description of Registrants Securities (Filed With SEC on March 13, 2020)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and David A. Cory (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and Stephana E. Patton (Filed With SEC on November 7, 2019)

Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger Biopharmaceuticals, Inc. and James Shaffer (Filed With SEC on November 7, 2019)

License Agreement, dated as of May 10, 2019, by and among the Trustees of the University of Pennsylvania and The Childrens Hospital of Philadelphia and Eiger Biopharmaceuticals,... (Filed With SEC on November 7, 2019)

Offer Letter, dated as of February 26, 2019, by and between Eiger BioPharmaceuticals, Inc. and Stephana Patton (Filed With SEC on May 9, 2019)

Offer Letter, dated as of November 30, 2018, by and between Eiger BioPharmaceuticals, Inc. and Sriram Ryali (Filed With SEC on May 9, 2019)

Third Amendment to Loan and Security Agreement, dated March 5, 2019, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on May 9, 2019)

Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, amended on May 7, 2019 (Filed With SEC on May 9, 2019)

Underwriting Agreement, dated April 17, 2019 (Filed With SEC on April 22, 2019)

Separation Agreement dated as of November 30, 2018, by and between Eiger BioPharmaceuticals, Inc. and James Welch (Filed With SEC on March 14, 2019)

First Amendment to Loan and Security Agreement, dated August 24, 2017, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on March 14, 2019)

Product Development Agreement, dated July 1, 2018, by and between Eiger BioPharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on November 9, 2018)

Common Stock Purchase Agreement, dated September 19, 2018, by and between Eiger BioPharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on November 9, 2018)

Product Assignment 1, dated July 1, 2018, by and between Eiger BioPharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on November 9, 2018)

Underwriting Agreement, dated as of October 23, 2018, by and between Eiger BioPharmaceuticals, Inc. and BTIG, LLC (Filed With SEC on October 23, 2018)

Master Services Agreement, dated April 26, 2018, by and between Eiger BioPharmaceuticals, Inc. and Clinigen Healthcare Ltd (Filed With SEC on August 10, 2018)

Amendment No. 6 to License Agreement, dated September 2, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on August 10, 2018)

Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and The Progeria Research Foundation (Filed With SEC on August 10, 2018)

Second Amendment to Loan and Security Agreement, dated May 11, 2018, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (Filed With SEC on August 10, 2018)

Purchase Agreement, dated as of May 24, 2018, by and between Eiger BioPharmaceuticals, Inc. and Piper Jaffray & Co (Filed With SEC on May 25, 2018)

First Amendment to Lease, dated April 26, 2018, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC (Filed With SEC on May 11, 2018)

Standard Multi-Tenant Office Lease Net, dated October 11, 2017, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC, and addendum thereto (Filed With SEC on March 9, 2018)

Offer Letter, dated as of December 12, 2017, by and between Eiger BioPharmaceuticals, Inc. and David Apelian, M.D., Ph.D (Filed With SEC on March 9, 2018)

Underwriting Agreement, dated October 27, 2017, by and between the Company and the Underwriter (Filed With SEC on October 30, 2017)

Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy (Filed With SEC on May 12, 2017)

LOAN AND SECURITY AGREEMENT (Filed With SEC on March 23, 2017)

Eiger BioPharmaceuticals, Inc. 2013 Employee Stock Purchase Plan Adopted by the Board of Directors: September 3, 2013 Approved by the Stockholders: October 10, 2013 Amended by the... (Filed With SEC on November 8, 2016)

Eiger BioPharmaceuticals, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by the Board of Directors: September 3, 2013 Approved by the Stockholders: October 10, 2013... (Filed With SEC on November 8, 2016)

1,250,000 EIGERBIOPHARMACEUTICALS, INC. UNDERWRITING AGREEMENT (Filed With SEC on August 19, 2016)

SUBSCRIPTION AGREEMENT (Filed With SEC on December 14, 2015)

MERGER INCENTIVE BONUS AGREEMENT (Filed With SEC on December 14, 2015)

L E A S E (Filed With SEC on December 14, 2015)

EIGER BIOPHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MAY 27, 2009 APPROVED BY THE STOCKHOLDERS:JULY 22, 2009 TERMINATION DATE: MAY 26, 2019... (Filed With SEC on December 14, 2015)

ASSET PURCHASE AGREEMENT (Filed With SEC on December 14, 2015)

ASSET PURCHASE AGREEMENT among: EIGER BIOPHARMACEUTICALS,INC., a Delaware corporation; and TRACEY MCLAUGHLIN ANDCOLLEEN CRAIG Dated as of September 25, 2015 ASSET PURCHASE... (Filed With SEC on December 14, 2015)

ASSET PURCHASE AGREEMENT among: EIGERBIOPHARMACEUTICALS, INC. a Delaware corporation; and EICCOSE, LLC, a Delaware limited liability company Dated as ofOctober 29, 2015 ASSET... (Filed With SEC on December 14, 2015)

EXCLUSIVE AGREEMENT (Filed With SEC on December 14, 2015)

LICENSE AGREEMENT (Filed With SEC on December 14, 2015)

AGREEMENTAND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on November 19, 2015)

SUPPORT AGREEMENT (Filed With SEC on November 19, 2015)

BONUS AGREEMENT (Filed With SEC on November 19, 2015)

SUBLEASE TERMINATION AND SETTLEMENT AGREEMENT (Filed With SEC on November 9, 2015)

AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (Filed With SEC on November 9, 2015)

CELLADON CORPORATION SUMMARY OF RETENTION PROGRAM Adopted April 26, 2015 Amended on May 13, 2015 (Filed With SEC on August 11, 2015)

AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (Filed With SEC on August 11, 2015)

EXHIBIT A RELEASE AGREEMENT (Filed With SEC on August 11, 2015)

DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on May 15, 2015)

AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 31, 2015)

Facility Construction andCommercial Supply Agreement (the Agreement) (Filed With SEC on March 31, 2015)

DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on March 31, 2015)

CELLADON CORPORATION [ l ] Shares of Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on August 7, 2014)

Material Transfer and Exclusivity Agreement (Filed With SEC on May 13, 2014)

EXHIBIT A RELEASE AGREEMENT (Tobe signed on or after the Separation Date) (Filed With SEC on January 28, 2014)

CELLADON CORPORATION Shares of Common Stock (par value $0.0001 per share) Underwriting Agreement (Filed With SEC on January 22, 2014)

CELLADON CORPORATION 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 3, 2013 AMENDED BY THE BOARD OFDIRECTORS: SEPTEMBER 11, 2013 APPROVED BY... (Filed With SEC on January 22, 2014)

INDEMNITY AGREEMENT (Filed With SEC on November 8, 2013)

CELLADON CORPORATION 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 3, 2013 AMENDED BY THE BOARD OFDIRECTORS: SEPTEMBER 11, 2013 APPROVED BY... (Filed With SEC on November 1, 2013)

CELLADON CORPORATION 2013 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 3, 2013 APPROVED BY THE STOCKHOLDERS:OCTOBER 10, 2013 (Filed With SEC on November 1, 2013)

CELLADON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on November 1, 2013)

Additional abbreviations may also be used though not in the above list. For value received, hereby sell(s), assign(s) and transfer(s) unto (Filed With SEC on October 29, 2013)

WARRANT TOPURCHASE SHARES OF SERIES A-1 PREFERRED STOCK of CELLADON CORPORATION INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE (Filed With SEC on October 29, 2013)

CELLADON CORPORATION 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 26, 2012 APPROVED BY THE SHAREHOLDERS:JANUARY 26, 2012 AMENDED BY THE BOARDOF DIRECTORS:... (Filed With SEC on October 29, 2013)

CELLADON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on October 29, 2013)

CELLADON CORPORATION Shares of Common Stock (par value $0.0001 per share) Underwriting Agreement (Filed With SEC on October 11, 2013)

CELLADON CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on October 11, 2013)

INDEMNITY AGREEMENT (Filed With SEC on October 11, 2013)

CELLADON CORPORATION 2001 STOCK OPTION PLAN (Filed With SEC on October 11, 2013)

CELLADON CORPORATION 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 26, 2012 APPROVED BY THE SHAREHOLDERS:JANUARY 26, 2012 AMENDED BY THE BOARDOF DIRECTORS:... (Filed With SEC on October 11, 2013)

CELLADON CORPORATION 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 3, 2013 APPROVED BY THE STOCKHOLDERS:OCTOBER 10, 2013 IPO DATE: ,2013 (Filed With SEC on October 11, 2013)

CELLADON CORPORATION 2013 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 3, 2013 APPROVED BY THE STOCKHOLDERS:OCTOBER 10, 2013 (Filed With SEC on October 11, 2013)

CELLADON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on October 11, 2013)

EXHIBIT A RELEASE AGREEMENT (Tobe signed on or after the Separation Date) (Filed With SEC on October 11, 2013)

STANDARD OFFICE LEASE BY AND BETWEEN ARDENREALTY LIMITED PARTNERSHIP, a Maryland limited partnership AS LANDLORD, AND CELLADON CORPORATION, a California corporation ASTENANT SUITE... (Filed With SEC on October 11, 2013)

LICENSEAGREEMENT BETWEEN CELLADONCORPORATION AND THE REGENTSOF THE UNIVERSITY OF CALIFORNIA FOR CASE NO. [...***...] CASE NO. [...***...] CASE NO.[...***...] CASE NO. [...***...]... (Filed With SEC on October 11, 2013)

EXCLUSIVELICENSE AGREEMENT (Filed With SEC on October 11, 2013)

NON-EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on October 11, 2013)

FOR THE PARTYOF THE FIRST PART Frank L. Graham President & Chief Executive Officer AdVec Inc. Ancaster, Ontario CANADA FOR THE PARTY OF THESECOND PART CELLADON CORPORATION 2223... (Filed With SEC on October 11, 2013)

UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on October 11, 2013)

NON-EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on October 11, 2013)

AMENDED ANDRESTATED LICENSE AGREEMENT (Filed With SEC on October 11, 2013)

SUBLICENSEAGREEMENT (Filed With SEC on October 11, 2013)

AMENDED ANDRESTATED MANUFACTURING SERVICES AGREEMENT (Filed With SEC on October 11, 2013)

Category

Industry

Companies

Contracts

Eiger BioPharmaceuticals, Inc. Contracts & Agreements